A device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle
The device addresses the inefficiency of manual serum extraction by using a mechanism for automatic serum extraction with a permeable membrane and limiting mechanism, improving the accuracy and efficiency of monoclonal antibody preparation for early pregnancy detection in cattle.
Patent Information
- Application Number
- CN202210641594.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-07
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-06-07
AI Technical Summary
Existing serum extraction devices require manual intervention and cannot automatically extract high-quality serum from blood samples post-centrifugation, limiting the efficiency and accuracy of monoclonal antibody preparation for early pregnancy detection in cattle.
A device comprising a box A, box B, test tube, and a driving assembly with extraction, pressure relief, and deceleration mechanisms that enable automatic serum extraction through linear and rotational motions, using a permeable membrane for filtration, and a limiting mechanism to fix test tubes, ensuring high-quality serum extraction.
The device achieves rapid and automatic serum extraction with reduced impurities, enhancing the success rate and accuracy of monoclonal antibody preparation for early pregnancy detection in cattle.
Smart Images

Figure CN115057929B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of cell engineering, and in particular relates to a device for rapid detection of monoclonal hybridoma cell lines in early pregnancy of cattle. Background Art
[0002] Accurate and timely pregnancy detection of cattle is a very important part of today's ranch breeding management program. The existing technology uses monoclonal antibodies containing anti-bovine early pregnancy factor to detect pregnancy in cattle. During the antibody preparation process, a centrifugal device is required to obtain the corresponding serum to complete the antibody preparation.
[0003] A Chinese patent with announcement number CN110152895B proposes a serum extraction centrifugal separation device, including a fixed seat, a fixed shell, a connecting pipe and a rotating seat. The fixed seat is fixedly provided with a fixed shell, and a rotating seat is arranged inside the fixed shell. A driven wheel is fixedly connected to the rotating seat, and a motor is fixedly connected to the driven wheel. The output shaft of the motor is fixedly connected to a driving wheel, and the driving wheel and the driven wheel are connected by a belt. Blood collection tube placement grooves and serum tube placement grooves are evenly provided inside the rotating seat, and an inner cover is provided on the rotating seat. The inner cover is provided with perforations. The device is provided with multiple blood collection tube placement grooves and connected through a connecting pipe, and the setting of the positioning sleeve facilitates the fixing of the connecting pipe. At the same time, the setting of the scale line facilitates quantitative control of the insertion amount of the connecting pipe, avoids incomplete separation, and improves the separation quality.
[0004] Although the above device further solves the problem that the existing serum extraction device requires a single separate blood collection tube, it still cannot automatically extract high-quality serum from the blood sample tube after centrifugation. Summary of the invention
[0005] In view of the deficiencies in the prior art, the present invention provides a device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle, which solves the above problems.
[0006] To achieve the above objectives, the present invention is implemented through the following technical solutions: A device for rapid detection of monoclonal hybridoma cell lines in early pregnancy of cattle, comprising a box A, a box B, a test tube and a driving assembly, wherein the test tube is slidably matched with a sponge plug embedded in the box B, and the box B is rotatably connected to the box A through a main shaft, and further comprising:
[0007] An extraction mechanism, connected to the box A, is used to extract serum, the extraction mechanism comprises a top plate, a placement component, a pressure relief component and a speed reduction component, and the top plate is connected to the box B through the push component A;
[0008] The pressure relief assembly includes a sleeve A, a connecting column A, an elastic member A and a connecting column B, wherein the sleeve A is rotatably connected to the top plate, the connecting column A is rotatably connected to the connecting column B, the elastic member A is located in the sleeve A and one end is connected to the sleeve A, and the other end of the elastic member A is connected to the connecting column A;
[0009] The deceleration assembly includes a push rod and a sliding column, the sliding column is connected to the push rod, the sliding column is slidably matched with a groove opened on the sleeve A, the push rod is connected to the connecting column B, and the push rod is connected to the placement assembly;
[0010] The pushing component A pulls the top plate to perform linear reciprocating motion, causing the placement component to be inserted into or away from the test tube. The driving component drives the box B to rotate through the main shaft, causing the test tube to perform centrifugal motion. At the same time, the connecting column A and the connecting column B rotate synchronously and pull the elastic part A under their own inertia, causing themselves to move linearly along the sleeve A. The connecting column B pushes the push rod to move linearly. The sliding column slides along the groove opened on the sleeve A under the push of the push rod and causes the push rod to push the placement component to perform slow linear motion along the inner wall of the test tube to perform membrane filtration of the serum, thereby realizing rapid and automatic extraction of the serum.
[0011] On the basis of the above technical solution, the present invention also provides the following optional technical solution:
[0012] Further technical solution: The box body A is provided with a limiting mechanism for fixing the test tube.
[0013] Further technical solution: the placement component includes a cylinder, a mounting plate and a permeable membrane, the permeable membrane is connected to the mounting plate, the mounting plate is threadedly connected to the cylinder, the cylinder is slidably matched with the test tube, a sealing cover is threadedly connected to the cylinder, and the sealing cover is connected to the push rod through the adsorption component B.
[0014] Further technical solution: The pushing component A includes a sleeve B, a connecting rod C and an elastic member B, the connecting rod C is slidingly matched with the sleeve B, the elastic member B is located inside the sleeve B, and the sleeve B and the connecting rod C are connected via the adsorption component A.
[0015] Further technical solution: the driving assembly includes a motor and a gear pair, the motor is connected to the box A, and the output shaft of the motor is connected to the main shaft through the gear pair.
[0016] Further technical solution: The limiting mechanism includes a limiting member, a sleeve C and a mounting plate, wherein the sleeve C is connected to the box A, and further includes:
[0017] A pushing component B is connected to the limiting member and the mounting plate and is used to push the limiting member to squeeze the test tube; and
[0018] The linear motion component is connected to the sleeve C and the mounting plate, and is used to push the mounting plate to perform linear motion in the vertical direction.
[0019] Further technical solution: the adsorption component A includes an electromagnet A and an electromagnet B, the electromagnet A is embedded in and connected to the connecting rod C, and the electromagnet B is connected to the sleeve B.
[0020] Further technical solution: the linear motion assembly includes a rotating block and a screw rod, the rotating block is connected to the screw rod, the screw rod is threadedly connected to the sleeve C, and the screw rod is rotationally connected to the mounting plate.
[0021] Further technical solution: the pushing assembly B includes a connecting rod A and a connecting rod B, the connecting rod A is rotatably connected to the connecting rod B, the connecting rod B is rotatably connected to the limiter, the connecting rod B is slidably matched with the sponge plug, and the connecting rod A is rotatably connected to the mounting plate.
[0022] Further technical solution: a roller is embedded in the box A, the roller is rotatably connected to the box A, and the roller is in conflict with the box B.
[0023] Beneficial Effects
[0024] The present invention provides a device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle. Compared with the prior art, it has the following beneficial effects:
[0025] 1. The pushing component A can make the placement component insert into or away from the test tube placed in the sponge plug by pulling the top plate to make a linear reciprocating motion in the vertical direction. The driving component drives the box body B to make a rotational motion in the vertical direction through the main shaft to make the test tube to make a centrifugal motion. At the same time, the connecting column A and the connecting column B rotate synchronously and pull the elastic member A under their own inertia to make themselves move linearly along the sleeve A. The connecting column B pushes the push rod to move linearly. The push rod pushes the sliding column to slide along the slot opened on the sleeve A to make the push rod push the placement component to move slowly linearly along the inner wall of the test tube, thereby achieving a technical effect of rapid and automatic extraction of serum;
[0026] 2. By twisting the rotating block to rotate, the screw rod can move linearly in the vertical direction along the sleeve C threadedly connected thereto, so as to push the mounting plate to move linearly in the vertical direction. At the same time, the mounting plate drives the pushing component to push the limiting member to squeeze several test tubes, thereby achieving the technical effect of limiting and fixing the test tubes;
[0027] 3. The permeable membrane placed in the component can accurately filter the serum, ensuring that the filtered serum does not contain excess impurities, which can effectively improve the success rate and accuracy of monoclonal antibody preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Schematic diagram of the distribution of components of the present invention.
[0029] Figure 2 It is a schematic diagram of the overall structure of the present invention.
[0030] Figure 3 This is an enlarged view of the structure of part A of the present invention.
[0031] Figure 4 It is an enlarged view of the structure of part B of the present invention.
[0032] Figure 5 This is an enlarged view of the C part structure of the present invention.
[0033] Figure 6 It is an enlarged view of the D part structure of the present invention.
[0034] Figure 7 It is a schematic diagram of the structure of the limiting mechanism of the present invention.
[0035] Notes on the figure numbers: 1. Box body A; 2. Box body B; 3. Sponge plug; 4. Test tube; 5. Placement assembly; 6. Top plate; 7. Push assembly A; 8. Limiting mechanism; 9. Main shaft; 10. Drive assembly; 11. Gear pair; 12. Roller; 13. Cylinder; 14. Sleeve A; 15. Mounting plate; 16. Permeable membrane; 17. Sealing cover; 18. Push rod; 19. Connecting column A; 20. Elastic part A; 21. Sliding column; 22. Connecting column B; 23. Connecting rod A; 24. Connecting rod B; 25. Limiting part; 26. Sleeve B; 27. Electromagnet A; 28. Connecting rod C; 29. Elastic part B; 30. Electromagnet B; 31. Rotating block; 32. Sleeve C; 33. Screw; 34. Mounting disk; 35. Motor. DETAILED DESCRIPTION
[0036] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0037] The specific implementation of the present invention is described in detail below in conjunction with specific embodiments.
[0038] See also Figures 1 to 5 , provided in one embodiment of the present invention, is a device for rapid detection of monoclonal hybridoma cell lines in early pregnancy of cattle, comprising a box A1, a box B2, a test tube 4 and a driving assembly, wherein the test tube 4 is slidably matched with a sponge plug 3 embedded in the box B2, and the box B2 is rotatably connected to the box A1 through a main shaft 9, and further comprising:
[0039] The extraction mechanism is connected to the box A1 and is used to extract serum. The extraction mechanism includes a top plate 6, a placement component 5, a pressure relief component and a speed reduction component. The top plate 6 is connected to the box B2 through a push component A7.
[0040] The pressure relief assembly includes a sleeve A14, a connecting column A19, an elastic member A20 and a connecting column B22. The sleeve A14 is rotatably connected to the top plate 6, the connecting column A19 is rotatably connected to the connecting column B22, the elastic member A20 is located in the sleeve A14 and one end is fixedly connected to the sleeve A14, and the other end of the elastic member A20 is fixedly connected to the connecting column A19;
[0041] The deceleration assembly includes a push rod 18 and a sliding column 21, the sliding column 21 is fixedly connected to the push rod 18, the sliding column 21 is slidably matched with a groove opened on the sleeve A14, the push rod 18 is fixedly connected to the connecting column B22, and the push rod 18 is connected to the placement assembly 5;
[0042] The pushing component A7 pulls the top plate 6 to perform a vertical linear reciprocating motion to cause the placement component 5 to be inserted into or away from the test tube 4 placed in the sponge plug 3. The driving component drives the box B2 to perform a vertical rotational motion through the main shaft 9 to cause the test tube 4 to perform a centrifugal motion. At the same time, the connecting column A19 and the connecting column B22 rotate synchronously and pull the elastic part A20 under their own inertia to cause themselves to perform a linear motion along the sleeve A14. The connecting column B22 pushes the push rod 18 to perform a linear motion. The push rod 18 pushes the sliding column 21 to slide along the groove provided on the sleeve A14, causing the push rod 18 to push the placement component 5 to perform a slow linear motion along the inner wall of the test tube 4 to perform membrane filtration of the serum, thereby realizing rapid and automatic extraction of the serum.
[0043] Preferably, the groove is a spiral groove.
[0044] Preferably, the elastic member A20 is any one of a spring, a compression spring and an elastic steel plate.
[0045] Preferably, the placement assembly 5 includes a barrel 13, a mounting plate 15 and a permeable membrane 16, the permeable membrane 16 is fixedly connected to the mounting plate 15, the mounting plate 15 is threadedly connected to the barrel 13, the barrel 13 and the test tube 4 are slidably matched, a sealing cover 17 is threadedly connected to the barrel 13, and the sealing cover 17 is connected to the push rod 18 through the adsorption assembly B. The purpose of this arrangement is to extract serum from the blood using the permeable membrane arranged on the mounting plate 15 and place it in the barrel 13.
[0046] Preferably, a roller 12 is embedded in the box A1, the roller 12 is rotatably connected to the box A1, and the roller 12 contacts the box B2. The purpose of this arrangement is to reduce the friction between the box A1 and the box B2, and to support the box B2.
[0047] Preferably, a one-way valve (not shown) is provided in the barrel 13, and the one-way valve is fixedly connected to the barrel 13. The purpose of this arrangement is to prevent the serum in the barrel 13 from flowing back.
[0048] Preferably, the adsorption component is an electromagnet.
[0049] Preferably, the pushing assembly A7 includes a sleeve B26, a connecting rod C28 and an elastic member B29, the connecting rod C28 is slidably matched with the sleeve B26, the elastic member B29 is located in the sleeve B26, and the sleeve B26 and the connecting rod C28 are connected through the adsorption assembly A. The adsorption assembly A drives the sleeve B26 to perform linear reciprocating motion in the vertical direction, and the sleeve B26 achieves the technical effect of pushing the placement assembly 5 to approach or move away from the test tube 4 by pulling the top plate 6 to perform linear reciprocating motion in the vertical direction.
[0050] Preferably, the adsorption assembly A includes an electromagnet A27 and an electromagnet B30, wherein the electromagnet A27 is embedded in and fixedly connected to the connecting rod C28, and the electromagnet B30 is fixedly connected to the sleeve B26. The purpose of this arrangement is to utilize the properties of the electromagnet A27 and the connecting rod C28 that opposite poles repel each other and attract each other, thereby causing the connecting rod C28 to perform a linear reciprocating sliding along the sleeve B26.
[0051] Preferably, the elastic member B29 is any one of a spring, a compression spring and an elastic steel plate.
[0052] Preferably, the driving assembly 10 includes a motor 35 and a gear pair 11, the motor 35 is fixedly connected to the housing A1, and the output shaft of the motor 35 is transmission-connected to the spindle 9 via the gear pair 11. The purpose of this arrangement is to use the gear pair 11 to transmit the rotational motion of the motor 35 to the spindle 9, so as to cause the spindle 9 to perform a vertical rotational motion, so as to achieve the technical effect of driving the housing B2 to rotate in the vertical direction.
[0053] In an embodiment of the present invention, the pushing component A7 pulls the top plate 6 to perform a vertical linear reciprocating motion to cause the placement component 5 to be inserted into or away from the test tube 4 placed in the sponge plug 3. The driving component drives the box B2 to perform a vertical rotational motion through the main shaft 9 to cause the test tube 4 to perform a centrifugal motion. At the same time, the connecting column A19 and the connecting column B22 rotate synchronously and pull the elastic part A20 under their own inertia to cause themselves to move linearly along the sleeve A14. The connecting column B22 pushes the push rod 18 to move linearly. The push rod 18 pushes the sliding column 21 to slide along the groove opened on the sleeve A14 and causes the push rod 18 to push the placement component 5 to perform a slow linear motion along the inner wall of the test tube 4 to perform membrane filtration of the serum, thereby realizing rapid and automatic extraction of the serum.
[0054] See also Figure 1 , Figure 2 as well as Figure 7 As an embodiment of the present invention, a limiting mechanism 8 for fixing the test tube 4 is provided on the box body A1.
[0055] Preferably, the limiting mechanism 8 includes a limiting member 25, a sleeve C32 and a mounting plate 34, wherein the sleeve C32 is fixedly connected to the box body A1, and further includes:
[0056] A pushing component B, connected to the limiting member 25 and the mounting plate 34, and used to push the limiting member 25 to squeeze the test tube 4; and
[0057] The linear motion component is connected to the sleeve C32 and the mounting plate 34, and is used to push the mounting plate 34 to perform linear motion in the vertical direction. The linear motion component pushes the mounting plate 34 to perform linear motion in the vertical direction in the box A1, and the mounting plate 34 drives the pushing component to push the limiting member 25 to squeeze the test tubes 4, thereby achieving the technical effect of limiting and fixing the test tubes 4.
[0058] Preferably, the linear motion assembly includes a rotating block 31 and a screw 33, wherein the rotating block 31 is fixedly connected to the screw 33, the screw 33 is threadedly connected to the sleeve C32, and the screw 33 is rotatably connected to the mounting plate 34. The purpose of this arrangement is to enable the screw 33 to perform linear motion in the vertical direction along the sleeve C32 threadedly connected thereto by twisting the rotating block 31 to rotate, thereby achieving the technical effect of pushing the mounting plate 34 to perform linear motion in the vertical direction.
[0059] Preferably, the pushing assembly B includes a connecting rod A23 and a connecting rod B24, the connecting rod A23 is rotatably connected to the connecting rod B24, the connecting rod B24 is rotatably connected to the stopper 25, the connecting rod B24 is slidably matched with the sponge plug 3, and the connecting rod A23 is rotatably connected to the mounting disk 34. The connecting rod A23, driven by the mounting disk 34, pushes the connecting rod B24 to slide along the groove provided on the sponge plug 3, thereby achieving the technical effect of pushing the stopper 25 to press the test tube 4.
[0060] Preferably, the stopper 25 is any one of an arc-shaped plate, a C-shaped plate and a V-shaped plate. The purpose of this arrangement is to increase the contact area between the stopper 25 and the test tube 4 and to provide a stable contact to the test tube 4.
[0061] In the embodiment of the present invention, the purpose of this arrangement is to limit and fix a plurality of test tubes 4 .
[0062] The method for preparing a monoclonal antibody of a cell line of an anti-bovine early pregnancy factor monoclonal antibody by using the device for blood centrifugation extraction comprises the following steps:
[0063] The method for preparing a monoclonal antibody of a cell line of an anti-bovine early pregnancy factor monoclonal antibody by using the device for blood centrifugation extraction comprises the following steps:
[0064] Step 1: Establish anti-torsion early pregnancy factor monoclonal antibody cell line, obtain antigen epitope immune polypeptide through epitope prediction, cross-link with carrier KLH, immunize mice to obtain antiserum and measure the titer, fuse SP2 / 0 cells with mouse spleen cells, clone cells to obtain hybridoma cells that can stably pass and secrete anti-bovine early pregnancy monoclonal antibodies, and screen positive clones;
[0065] Step 2: Prepare monoclonal antibodies, collect positive clones of the anti-bovine early pregnancy factor monoclonal antibody cell line established in S1, perform intraperitoneal injection on mice, collect ascites, remove cells, remove impurities, clarify, and use Protein G chromatography column to affinity purify the monoclonal antibodies;
[0066] The specific steps are:
[0067] S1: Antigen synthesis
[0068] S1.1 Epitope prediction
[0069] Using the amino acid residue protein sequence of bovine early pregnancy factor as a template, the antigen epitope was predicted by software analysis, and 5 segments of antigen epitope sequences were obtained. A cysteine was added to each segment at the N-terminus or C-terminus to facilitate cross-linking with the carrier.
[0070] Bovine early pregnancy factor protein sequence:
[0071] IVKIPLRRLK TMRNVVSGKN MLNNFLKEHA YSLASQISFR
[0072] GSNLTTHPLR NIKDLVYMGN ITIGTPPQEF QVVFDTASSD
[0073] LWVPSDFCTS PACSTHVRFR HLQSSTFRLT NKTFRITYGS
[0074] GRMKGVVVHD TVRIGNLVST DQPFGLSIEE YGFEGRIYDG
[0075] VLGLNYPNISFSGAIPIFDKLKNQRAISEPVFAFYLSKDE
[0076] REGSVVMFGG VDHRYYEGEL NWVPLIQAGD WSVEMDRISI
[0077] ERKIIACSDG CKALVDTGTS DIVGPRRLVN NIHRLIGAIP
[0078] RGSEHYVPCS EVNTLPSIVF TINGINYPVP GRAYILKDDR
[0079] GRCYTTFQEN RVSSSTETWY LGDVFLRLYF SVFDRGNDRI
[0080] GLARAV(SEQ NO.1)
[0081] Antigen epitopes obtained through software analysis:
[0082] CFDRGNDRIGLARAV(SEQ NO.2)
[0083] VDHRYYEGELNWC (SEQ NO.3)
[0084] CLKNQRAISEP(SEQ NO.4)
[0085] CSKDEREGSVVM(SEQ NO.5)
[0086] CKDDRGRCYTT(SEQ NO.6)
[0087] S1.2 Cross-linking of immune peptides with carrier KLH
[0088] The two-step method of carbodiimide hydrochloride (EDC·HCl) is adopted: 10-20 mg of polypeptide, 50-150 mg of EDC·HCl, and 5-20 mg of NHS are weighed in a single-mouth bottle, 1-4 ml of DMF is added to fully dissolve it, a magnetic stirrer is placed, sealed to avoid light, and reacted at room temperature for 10-20 hours to obtain a polypeptide reaction solution, which is liquid A; 10-50 mg of KLH is weighed and fully dissolved in 1-8 ml of phosphate buffer (PBS) to obtain liquid B; liquid A is added dropwise to liquid B, sealed to avoid light, and stirred overnight at 2-8 degrees Celsius. The above reaction solution is transferred to a dialysis bag pretreated with PBS for 10-32 hours, stirred on a magnetic stirrer at 2-8 degrees Celsius, and dialyzed with PBS for 12-72 hours. The liquid is changed several times during the dialysis process, and the cross-linked product of polypeptide-KLH produced after dialysis is freeze-dried.
[0089] S2: Establishment of monoclonal antibody cell lines
[0090] S2.1 Immunization of mice
[0091] The five polypeptide-KLH cross-linked products were mixed in equal amounts and used as immune antigens to immunize Balb / c pure strain mice.
[0092] a. Primary immunization: Take 30-150 μg of antigen from each mouse, mix with an equal amount of Freund's complete adjuvant and fully emulsify, and inject subcutaneously at multiple points on the back of the mouse's neck;
[0093] b. Second immunization: 3 weeks after the first immunization, take the same dose of antigen as the first one, emulsify it with an equal amount of Freund's incomplete adjuvant, and inject it subcutaneously at multiple points on the back of the mouse's neck;
[0094] c. The third immunization: 3 weeks after the second immunization, the same dose of antigen dissolved in saline is injected intraperitoneally;
[0095] d. 5-15 days after the end of immunization, the mice are tail-cut and blood is collected, and the separation device of the present invention is used to separate the antiserum. Specifically, the pushing component A7 pulls the top plate 6 to perform a vertical linear reciprocating motion to prompt the placement component 5 to insert into or move away from the test tube 4 placed in the sponge plug 3. The driving component drives the box B2 to perform a vertical rotational motion through the main shaft 9 to prompt the test tube 4 to perform a centrifugal motion. At the same time, the connecting column A19 and the connecting column B22 rotate synchronously and pull the elastic member A20 under their own inertia to prompt themselves to perform a linear motion along the sleeve A14. The connecting column B22 pushes the push rod 18 to perform a linear motion. The push rod 18 pushes the sliding column 21 to slide along the groove opened on the sleeve A14 and prompts the push rod 18 to push the placement component 5 to perform a slow linear motion along the inner wall of the test tube 4 to perform membrane filtration of the serum, thereby realizing rapid and automatic extraction of the serum.
[0096] S2.2 Antiserum titer detection
[0097] The titer of antibodies against bovine pregnancy factor protein was determined by indirect ELISA.
[0098] a. Antigen treatment: dilute the bovine early pregnancy factor protein to 1-5 μg / ml with PBS, add 100 μl to each well of the ELISA plate, incubate at 2-8°C overnight, wash the plate 3 times, take 1-5% BSA blocking solution, add 100-300 μl to each well of the ELISA plate, incubate at room temperature for 1-3 hours, and wash the plate.
[0099] b. Sample processing: Take the antiserum and make a doubling dilution starting from 1:500. Take 100 μl and add it to each well of the ELISA plate in turn. Incubate at 37 degrees Celsius for 1 hour. Wash the plate 3 times. Add 100 μl of HRP-labeled goat anti-mouse Ig (H+L) to each well. Incubate at 37 degrees Celsius for 30 minutes. Wash the plate 3 times. Add 100 μl of TMB substrate. Color develop at room temperature in the dark for 5-15 minutes. Add 50 μl of stop solution.
[0100] c. Determination: The OD value was determined using an enzyme marker (detection wavelength: 450 nanometers, reference wavelength: 630 nanometers). The test results are shown in Table 1.
[0101] Table 1 Mouse antiserum titer ELISA test results
[0102] Antiserum dilution 1# 2# 3# 4# 5# 1∶500 1.936 0.785 1.147 0.746 1.297 1∶1000 0.947 0.43 0.671 0.584 0.867 1∶2000 0.682 0.305 0.387 0.39 0.541 1∶4000 0.409 0.167 0.179 0.188 0.292 1∶8000 0.247 0.117 0.142 0.154 0.191 1∶16000 0.158 0.096 0.105 0.122 0.126 1∶32000 0.124 0.087 0.087 0.088 0.093 PBS 0.082 0.082 0.08 0.084 0.077
[0103] The results showed that the antibody titers of mouse antiserum diluted 1:32000 were higher than those of the control PBS, and the antibody level met the requirements for cell fusion.
[0104] S2.3 Establishment of hybridoma cells
[0105] a. Myeloma cell culture: 5-10 days before fusion, resuscitate SP2 / 0 cells, subculture in RPMI-1640 medium containing 5-10% FBS, collect SP2 / 0 cells in the logarithmic growth phase into a 50 ml centrifuge tube, count, take 1-5×107 myeloma cells, centrifuge at 1000-1500 rpm for 5-10 minutes, discard the supernatant, add 20-50 μl of serum-free RPMI-1640, and wash twice;
[0106] b. Shock immunization: 3-5 days before fusion, take the polypeptide-KLH cross-linked immune antigen and perform shock immunization on mice that have been immunized three times, with 30-150 μg of antigen injected intraperitoneally into each mouse;
[0107] c. Preparation of trophoblast cell plates: One day before fusion, mice were killed by cervical dislocation, and the mice were immersed in 75% alcohol for disinfection for 3-5 minutes, then moved to a clean bench, cut the abdominal skin, bluntly dissected, cut the peritoneum, aspirated 1-5 ml of serum-free culture medium, injected into the abdominal cavity for 2-3 times, and aspirated into a centrifuge tube. Centrifuged at 1000-1500 rpm for 5-10 minutes, discarded the supernatant, and the mouse peritoneal macrophages were transferred into an appropriate amount of complete culture medium and mixed, and 5 trophoblast cell plates were prepared. The trophoblast cell suspension was added to a 96-well plate, incubated at 37 degrees Celsius for 10-24 hours, and 0.5-1.5 ml of PEG and 5-20 ml of serum-free RPMI-1640 were placed in a 37-degree Celsius incubator for preheating;
[0108] d. Preparation of mouse immune spleen cells: remove the eyeballs of the immunized mice, bleed them, and kill them by myelotomy. Soak them in 75% alcohol for disinfection for 3-5 minutes. Under aseptic conditions, cut the abdominal cavity, remove the spleen, place the spleen on a 200-mesh steel mesh, add a small amount of RPMI-1640 to grind it, and make a spleen single cell suspension. Transfer it to a 50-ml centrifuge tube, add RPMI-1640 to 20-40 ml, centrifuge at 1000-1500 rpm for 5-10 minutes, and wash twice.
[0109] e. Cell fusion: Myeloma cells and spleen cells were fully mixed, RPMI1-1640 was added, and centrifuged at 1000-1500 rpm for 5-10 minutes, and the supernatant was discarded. Slowly add 0.5-1.5 ml of PEG preheated at 37 degrees Celsius within 30-60 seconds. After reacting for 30-60 seconds, add 5-20 ml of serum-free culture medium to terminate the effect of PEG. This operation is slow at first and then fast. Add 1 ml every 1-3 minutes. After adding 2 ml, the remaining culture medium should be added within 3-5 minutes. Centrifuge at 1000-1500 rpm for 5-10 minutes, discard the supernatant, add 10-30 ml of RPMI-1640 containing 5-20% FBS, mix gently by pipetting, add the cells to 5 96-well plates that have been plated with trophoblasts, add HAT selective culture medium one day later, observe the cell morphology every day, and after adding HAT for 3-5 days, the fused cells will form a single clone. At this time, use a negative pressure aspirator to suck out 1 / 3-1 / 2 of the culture medium and add new HAT culture medium. During the cell culture process, the medium is changed 1-3 times to prepare for hybridoma cell screening. The medium must be changed the day before screening. Generally, 8-15 days after fusion, the unfused myeloma cells and other cells are all dead, and the fused cells grow in clones. Cell screening can be performed when the cells fill the lower 1 / 2 or 2 / 3 of the well.
[0110] f. Positive screening of cell subclones: The indirect ELISA screening method is used to identify fused cells in the cell culture medium to determine whether specific antibodies are produced. The screening method is the same as the detection of antiserum titer, with the difference that the sample is the supernatant of monoclonal cell culture, and the myeloma cell culture medium is used as a control to perform cell subcloning on the positive wells. The day before subcloning, a mouse peritoneal macrophage nutrient plate is prepared, and the cells to be subcloned are gently blown to make a single cell suspension, added to a counting plate, and the cell density is calculated. Based on 100 cells per plate, the required volume is taken and added to an appropriate amount of complete culture medium. After sufficient mixing, it is added to a 96-well plate.
[0111] S2.4 Hybridoma cell subtype detection
[0112] Positive screening of cell subclones: The indirect ELISA screening method identifies fused cells in the cell culture medium to determine whether specific antibodies are produced. The screening method is the same as the detection of antiserum titer, with the difference that the sample is the supernatant of monoclonal cell culture. At the same time, myeloma cell culture medium is used as a control. Cell subcloning is performed on the positive wells. The mouse peritoneal macrophage trophoblast plate is prepared one day before subcloning. The cells that need to be subcloned are gently beaten to make a single cell suspension, added to the counting plate, and the cell density is calculated. Based on 100 cells per plate, the required volume is taken and added to an appropriate amount of complete culture medium. After sufficient mixing, it is added to a 96-well plate.
[0113] Table 2 Hybridoma cell ELISA test results
[0114] 2A1 2D8 3H7 5A3 6E4 A 1.505 1.188 1.467 0.727 1.362 B 1.495 1.108 1.153 0.676 0.605 C 1.308 1.099 0.527 0.537 0.178 D 0.96 0.736 0.171 0.32 0.072 E 0.427 0.328 0.09 0.156 0.058 F 0.165 0.136 0.06 0.077 0.05 G 0.088 0.069 0.057 0.085 0.071 H 0.06 0.063 0.063 0.056 0.059
[0115] The supernatants of five hybridoma cells (2A1, 2D8, 3H7, 5A3, and 6E4) all reacted with bovine pregnancy factor.
[0116] Table 3 Hybridoma cell subtypes
[0117] Code of mab cl0nes Isotype 2A1 IgG1 / K 2D8 IgG1 / κ 3H7 IgG1 / κ 5A3 IgG2a / κ 6E4 IgG1 / κ
[0118] The light chains of the five monoclonal antibodies were all Kappa, of which four monoclonal antibodies (2M, 2D8, 3H7 and 6E4) were IgG1 subtype, and 5A3 was IgG2a subtype.
[0119] About the preparation of ascites in S1
[0120] After subclone screening, cell lines that can stably secrete specific antibodies are cultured. When the cells reach a certain number, they are centrifuged and collected. 2×105-1×106 cells are injected intraperitoneally into each mouse. One week before the mice are injected with hybridoma cell lines, 0.5 ml of liquid paraffin is injected to sensitize the mice. The condition of the mice is observed. 1-2 weeks after the injection of hybridoma cells, when the mice's abdomen is swollen, abdominal puncture is performed to collect ascites.
[0121] About ascites pretreatment in S2
[0122] Take fresh (or frozen) ascites, centrifuge at 1000-4000 rpm, 2-8 degrees Celsius for 10-20 minutes, take the supernatant, measure the volume of ascites supernatant, add 2-5 mg CaCl2 per ml of ascites supernatant, mix immediately, add 5-15 mg silica powder, mix, incubate the suspension at room temperature for 15-30 minutes, centrifuge at 4000-10000 rpm, 2-8 degrees Celsius for 10-20 minutes, collect the supernatant and filter it through a 0.22 micron filter to obtain clarified ascites.
[0123] S3: Protein G affinity purification
[0124] Take the Protein G chromatography column, thaw to room temperature before use, and pre-balance with 3-5 times the column bed volume of equilibrium buffer, turn on the peristaltic pump, recorder and UV monitor, adjust the baseline of the recorder and UV monitor, dilute the pretreated ascites with an equal volume of equilibrium buffer, load it into the Protein G chromatography column through the peristaltic pump, collect the effluent, continue to wash the column with equilibrium buffer to completely remove the impurities, to the baseline, replace the elution buffer, collect the elution peak with a collection tube containing an appropriate amount of neutralization buffer, and dialyze the purified antibody with excess 0.01M PBS at pH 7.4. During the period, the buffer was replaced 3 times, and the last dialysis was overnight. The dialyzed antibody can be ultrafiltered and concentrated to a concentration of >1 mg / ml. After concentration, the antibody is centrifuged at 5000-10000 rpm and 2-8 degrees Celsius for 5-15 minutes. Take the supernatant, filter and sterilize it with a disposable 0.22 micron filter, determine the titer of the purified antibody, and add a preservative to aliquot and freeze it. The results are shown in Table 4.
[0125] Table 4 Purified antibody titer
[0126] Purified antibody concentration 2A1 2D8 3H7 5A3 6E4 10000 2.113 1.147 1.116 1.282 0.834 2000 2.136 1.02 1.064 1.002 0.732 400 1.868 0.698 0.497 0.385 0.381 80 1.204 0.246 0.161 0.121 0.127 39 0.54 0.115 0.081 0.062 0.075 16 0.186 0.061 0.056 0.049 0.055 3.2 0.119 0.068 0.065 0.067 0.066 0 0.085 0.07 0.066 0.067 0.086
[0127] S4: Monoclonal Antibodies Crosslinked to HRP
[0128] Weigh 25 mg of HRP and dissolve it in 1.25% glutaraldehyde. Let it stand at room temperature overnight. Pass the solution through a Sephadex G-25 chromatography column and elute with saline. Control the flow rate to 1 ml per minute and collect the brown effluent. If the volume of the brown effluent is more than 5 ml, concentrate it to 5 ml with PEG and place it in a 25 ml beaker. Stir it slowly to obtain the HRP enzyme solution. Take 12.5 mg of the antibody to be labeled and dilute it to 5 ml with saline. Add it dropwise to the HRP enzyme solution while stirring. Add 0.25 ml of 1MPH9.5 carbonate buffer. , continue stirring for 3 hours, add 0.25 ml of 0.2M lysine, mix well, leave at room temperature for 2 hours, add an equal volume of saturated ammonium sulfate dropwise while stirring, leave at 4 degrees Celsius for 1 hour, centrifuge at 3000 rpm for half an hour, discard the supernatant, wash the precipitate twice with semi-saturated ammonium sulfate, dissolve in a small amount of pH7.4, 0.15M PBS, put the above solution into a dialysis bag, dialyze to remove ammonium ions (detected by naphthyl reagent), centrifuge at 10000 rpm for 30 minutes to remove the precipitate, collect the supernatant, which is the antibody and enzyme conjugate, and freeze it in aliquots.
[0129] For the double antibody sandwich detection of bovine early pregnancy factor protein, the checkerboard method was used to use monoclonal antibodies immunized with different polypeptides as capture antibodies or detection antibodies to evaluate their possibility of detecting bovine early pregnancy factor protein.
[0130] Capture antibody 5-20 μg / ml coating, 100 μl per well, overnight at 4°C, add 1 μg / ml and 0 μg / ml bovine early pregnancy factor protein, 100 μl per well, incubate at 37°C for 30-60 minutes, wash the plate 3 times, add 1-5 μg / ml HRP-labeled detection antibody per well, incubate at 37°C for 30 minutes, wash the plate 3 times, add 100 μl TMB substrate, color at room temperature in the dark for 5-15 minutes, add 50 μl stop solution, and measure OD value with microplate reader (detection wavelength: 450 nanometers, reference wavelength: 630 nanometers). The screening results are shown in Table 5.
[0131] Table 5 Results of chessboard screening of monoclonal antibodies against different peptides
[0132]
[0133] The antibody pair with background OD value <0.1 and positive well OD value >1.0 was selected to optimize the concentration of capture antibody and detection antibody, and the bovine early pregnancy factor was serially diluted to detect the standard curve. The test results are shown in Table 6.
[0134] Table 6 Results of 2D8-6E4 paired test for bovine early pregnancy factor
[0135]
[0136] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0137] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A device for rapid detection of monoclonal hybridoma cell lines in early pregnancy of cattle, comprising a box A (1), a box B (2), a test tube (4) and a drive assembly (10), wherein the test tube (4) is slidably matched with a sponge plug (3) embedded in the box B (2), and the box B (2) is rotatably connected to the box A (1) via a main shaft (9), characterized in that: Also includes: An extraction mechanism connected to the box A (1) and used for extracting serum, the extraction mechanism comprising a top plate (6), a placement component (5), a pressure relief component and a speed reduction component, the top plate (6) being connected to the box B (2) via a push component A (7); The pressure relief assembly comprises a sleeve A (14), a connecting column A (19), an elastic member A (20) and a connecting column B (22); the sleeve A (14) is rotatably connected to the top plate (6); the connecting column A (19) is rotatably connected to the connecting column B (22); the elastic member A (20) is located in the sleeve A (14) and one end is connected to the sleeve A (14); the other end of the elastic member A (20) is connected to the connecting column A (19); The deceleration assembly comprises a push rod (18) and a sliding column (21), wherein the sliding column (21) is connected to the push rod (18), the sliding column (21) is slidably matched with a groove provided on the sleeve A (14), the push rod (18) is connected to a connecting column B (22), and the push rod (18) is connected to the placement assembly (5); The pushing component A (7) pulls the top plate (6) to perform linear reciprocating motion, thereby causing the placement component (5) to be inserted into or away from the test tube (4). The driving component drives the box body B (2) to rotate through the main shaft (9), thereby causing the test tube (4) to perform centrifugal motion. At the same time, the connecting column A (19) and the connecting column B (22) rotate synchronously and pull the elastic member A (20) under their own inertia, thereby causing themselves to perform linear motion along the sleeve A (14). The connecting column B (22) pushes the push rod (18) to perform linear motion. The sliding column (21) slides along the groove provided on the sleeve A (14) under the push of the push rod (18) and causes the push rod (18) to push the placement component (5) to perform slow linear motion along the inner wall of the test tube (4) to perform membrane filtration on the serum, thereby realizing rapid and automatic extraction of the serum.
2. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 1, characterized in that: The box body A (1) is provided with a limiting mechanism (8) for fixing the test tube (4).
3. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 1, characterized in that: The placement component (5) comprises a cylinder (13), a mounting plate (15) and a permeable membrane (16); the permeable membrane (16) is connected to the mounting plate (15); the mounting plate (15) is threadedly connected to the cylinder (13); the cylinder (13) and the test tube (4) are slidably matched; a sealing cover (17) is threadedly connected to the cylinder (13); and the sealing cover (17) is connected to the push rod (18) via an adsorption component B.
4. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 1, characterized in that: The pushing assembly A (7) includes a sleeve B (26), a connecting rod C (28) and an elastic member B (29), wherein the connecting rod C (28) is slidably matched with the sleeve B (26), and the elastic member B (29) is located inside the sleeve B (26), and the sleeve B (26) and the connecting rod C (28) are connected via an adsorption assembly A.
5. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 1, characterized in that: The driving assembly (10) comprises a motor (35) and a gear pair (11); the motor (35) is connected to the housing A (1); and the output shaft of the motor (35) is transmission-connected to the main shaft (9) via the gear pair (11).
6. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 2, characterized in that: The limiting mechanism (8) comprises a limiting member (25), a sleeve C (32) and a mounting plate (34), wherein the sleeve C (32) is connected to the box body A (1), and further comprises: A pushing component B, connected to the limiting member (25) and the mounting plate (34), and used for pushing the limiting member (25) to squeeze the test tube (4); and The linear motion component is connected to the sleeve C (32) and the mounting plate (34) and is used to push the mounting plate (34) to perform linear motion in the vertical direction.
7. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 4, characterized in that: The adsorption assembly A comprises an electromagnet A (27) and an electromagnet B (30), wherein the electromagnet A (27) is embedded in and connected to a connecting rod C (28), and the electromagnet B (30) is connected to a sleeve B (26).
8. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 6, characterized in that: The linear motion assembly comprises a rotating block (31) and a screw rod (33), wherein the rotating block (31) is connected to the screw rod (33), the screw rod (33) is threadedly connected to a sleeve C (32), and the screw rod (33) is rotationally connected to a mounting plate (34).
9. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 6, characterized in that: The pushing assembly B comprises a connecting rod A (23) and a connecting rod B (24), wherein the connecting rod A (23) is rotatably connected to the connecting rod B (24), the connecting rod B (24) is rotatably connected to the limiting member (25), the connecting rod B (24) is slidably matched with the sponge plug (3), and the connecting rod A (23) is rotatably connected to the mounting plate (34).
10. The device for rapid detection of monoclonal hybridoma cell lines for early pregnancy in cattle according to claim 1, characterized in that: A roller (12) is embedded in the box body A (1), the roller (12) is rotatably connected to the box body A (1), and the roller (12) is in contact with the box body B (2).
Citation Information
Patent Citations
A serum extraction and centrifugation device
CN110152895B
Deproteinized calf blood extract and preparation process thereof
CN102908363A
Preparation method of anti-cattle early pregnancy factor monoclonal antibody cell line and monoclonal antibody
CN108314732A
Blood platelet separation device
CN108479121A
Serum extracting centrifuging separating device
CN110152895A
